National Newswatch

Liberals’ PMPRB scale-back not a “win” for Big Pharma or patients

May 24 2022 — Nigel Rawson and John Adams — Times Colonist columnist Lawrie McFarlane and CBC’s reporter Kelly Crowe wrongly claim that the federal Liberals sold out Canadians to Big Pharma when Health Minister Jean-Yves Duclos announced the government’s decision to cancel most of its revisions for the Patented Medicine Prices Review Board (PMPRB). McFarlane and Crowe, together with anyone else who believes the government conceded to the industry, […]

Does Canada adequately monitor the quality and safety of foreign-made pharmaceuticals?

May 16 2022 — Nigel Rawson and John Adams — In April 2022, just five months after granting approval for use of Covaxin, a COVID-19 vaccine developed and manufactured in India, the World Health Organization (WHO) publicly warned United Nations agencies against procuring the vaccine. An inspection of a Covaxin production facility revealed deficiencies in what are called good manufacturing practices (GMP) – standards that must be met to ensure medicines are […]

Prescription Drug Costs: Deceptive Reporting, Incomplete Analyses, Hidden Biases

Dec 15 2021 — Nigel Rawson and John Adams — Yet another academic report claims pharmaceutical costs are soaring in Canada due to new innovative costly medicines. The Canadian Institute for Health Information (CIHI) also recently released its annual trends in national health expenditure reporting that drugs constitute the second largest class of spending (14 percent) well behind hospitals (25 percent) but just ahead of physicians (13 percent). These […]

False Premise: Federal Regulation of Drug Prices as a Step to National Pharmacare

Sep 9 2021 — Nigel Rawson and John Adams — In his National Newswatch commentary, Dr. Raza, another Canadian academic from that bastion of red socialism, argues for a national pharmacare program to be made affordable by drastically reducing drug prices by federal regulation. He uses data from an Angus Reid survey conducted with four academics from the Universities of British Columbia and Toronto and Carleton University who […]

A National Strategy for Drugs for Rare Diseases in Canada should Prioritize Patients – not Cost Containment

Mar 11 2021 — Nigel Rawson and John Adams — The 2019 federal budget raised hope for Canadians living with rare diseases by proposing to invest up to $1 billion over two years starting in 2022-23, with up to $500 million per year ongoing, in a national strategy for high-cost drugs for rare diseases. As a response to the recommendation of the Advisory Council on […]

Exempting COVID medicines from new price controls: Ottawa hypocrisy

Oct 14 2020 — Nigel Rawson and John Adams — The federal government intends to drastically transform the rules of its tribunal that sets ceiling prices for new drugs and vaccines in Canada in January. Guidelines will be released imminently for how the new price controls will work. Key elements of the government’s plan have been strongly criticized by patients, drug developers and analysts since […]